Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

Phase 4

Recruiting

• Conditions: Dry Eye
• Interventions: Drug: nanomicellular cyclosporine 0.09%; Drug: Lifitegrast

• Registration Number: NCT04172961
• Lead Sponsor: Toyos Clinic

Brief Summary

This study will be a randomized, double-blind prospective in 3 clinical sites to compare the efficacy of two currently approved topical ophthalmic drops in the clearing central corneal staining in 90 days prior to elective cataract or LASIK surgery.

Detailed Description

The study will be a randomized, double-blind prospective study in 3 sites in the US to compare efficacy of improvement in central corneal staining with fluorescein dye evaluations at slit lamp exam, secondarily improvement in OSDI questionnaire with additional questions regarding dysgeusia, blurriness, and sensation of burning, improvements in corneal topography and improvements in Schirmer's testing. 100 study subjects 18-85 male or female will be enrolled in the Nashville, Beverly Hills and St. Louis areas who are generally healthy with central corneal staining and scheduled for uncomplicated phacoemulsification or uncomplicated LASIK.

Study Timeline

• Study First Submitted: 2019-11-18
• Study First Submitted QC: 2019-11-19
• Study First Posted: 2019-11-21
• Study Start: 2020-02-01
• Status Verified: 2022-10
• Last Update Submitted: 2022-10-18
• Last Update Posted: 2022-10-20
• Primary Completion: 2022-12-01
• Study Completion: 2022-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Subject is able to read, understand and sign informed consent.

2. Provision of signed and dated informed consent and HIPAA authorization .

3. Willingness to comply with study procedures and availabilty for duration of study.

4. Aged 18-85, male or female

5. Minimum of 5 central corneal superficial punctate keratitis spots.

6. Normal eyelid anatomy

7. highly effective contraception for at least 1 month prior to screening and agreement to use effective contraception during study participation and for an additional 4 weeks after study drug discontinuation.

8. Postmenopausal or surgical sterilization.

Exclusion Criteria

1. Known hypersensitivity or contraindication to investigational product.
2. Contact lens use within one month prior to screening
3. Unwilling to discontinue contact lens.
4. pregnancy or lactation.
5. topical or nasal vasoconstrictors within 14 days prior to screening or unable to refrain from same.
6. Ocular surgery or eyelid surgery within 6 months prior to screening
7. Subjects can be on the following medications if they have been on a stable dose for 12 weeks: loteprednol, tetracycline, omega 3, anticholinergics, anticonvulsants, antidepressants, retinoids, systemic immunosuppressives including oral steroids, non-steroidals, antihistamines, mast cell stabilizers, punctal plugs, corticotropin repository or glaucoma medications.
8. abstain from eyelast growth products containing prostaglandin
9. Must not have had penetrating intraocular surgery, refractive surgery, cornea transplant, eyelid surgery within 6 months prior to Visit 1
10. Febrile illness within 1 week
11. Treatment with another investigational drug or intervention within one month
12. History of herpetic keratitis.
13. Serious or severe disease or uncontrolled medical condition that in the judgment of the investigator could confound study study assessments or limit compliance.
14. Use of new prescription eyedrop within 90 days of screening.
15. Change in systemic medication within 90 days of screening
16. Anticipated relocation or extensive travel during study period. -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Nanomicellular Cyclosporine 0.09 prior to surgery	nanomicellular cyclosporine 0.09%	50 subjects receive nanomicellular cyclosporien 0.09% prior to elective ophthalmic surgery
Lifitegrast 5.0%	Lifitegrast	50 subjects receive liftigrast 5.0% prior to elective ophthalmic surgery

Primary Outcome Measures

Name	Time	Method
change in central corneal staining	90 days	use of fluorescein staining to count at slit lamp actual number of central cornea spk

Secondary Outcome Measures

Name	Time	Method
change in OSDI questionnaire with additional questions of dysgeusia, blurriness and sensation of burning	90 days	subjective improvement of symptoms and assessment of adverse events
change in corneal topography	90 days	variation in measurements of corneal topography
change in Schirmers testing	90 days	change in Schirmers testing

Trial Locations

Locations (1)

Toyos Clinic; 🇺🇸 Nashville, Tennessee, United States